In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Role Reversal: Big Pharma Provides Rich Pickings for Biotech

Executive Summary

Big Pharma is looking for innovative ways to realize value from non-core assets--including discovery technologies. The U.K.'s Proteome Sciences is the latest European biotech to benefit, as Aventis clears out its house.

Related Content

Exelixis: Bartering for Growth
BioXell: A New Beginning for Italian Biotech
The Foundations of High-Value Discovery Deals


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts